Sell4

KESTRA MEDICAL TECHNOLOGIES, LTD.

KMTS

Total Value

$1.9M

Net $900.9K sold

Filing Date

Oct 29, 2026

1 transaction

Sales

$900.9K

1 transaction

Trade Summary

On Oct 27, 2026, Umberger Traci S, Insider, sold $1.9M of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) across 1 transaction. The filing covers Common Shares and reflects net selling of $900.9K. Reported prices ranged from $17.00 to $30.03. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

KMTS daily price with the insider's sale marked at $30.03.

Sold near the 6-month high · the stock trades 4% lower today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Umberger Traci S
Role: Insider
Location: KIRKLAND, WA

Filing Details

Filing Date: Oct 29, 2026
Transaction Date: Oct 27, 2026
Accession Number: 0001193125-26-438662
Form Type: 4
Net Trading Amount: -$900.9K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 27, 2026	Common Shares	30,000	$17.00	Exercise	$510.0K
Oct 27, 2026	Common Shares	30,000	$30.03	Sale	$900.9K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 27, 2026	KMTS derivative	30,000	$17.00	Exercise	$510.0K

Want live alerts when Umberger Traci S trades again?

Download Insider Trades to track KMTS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
(F2)The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4202. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
(F3)Includes 365,919 fully vested options as of the filing date, with the remaining 45,081 options vesting in equal monthly installments through March 6, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Umberger Traci S

(Last)

(First)

(Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND

98033

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	10/27/2026		M⁽¹⁾		30,000	A	$17	225,825	D
Common Shares	10/27/2026		S⁽¹⁾		30,000	D	$30.0294⁽²⁾	195,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options	$17	10/27/2026		M			30,000	⁽³⁾	03/06/2035	Common Stock	30,000	$0	411,000	D

Explanation of Responses:

1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4202. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. Includes 365,919 fully vested options as of the filing date, with the remaining 45,081 options vesting in equal monthly installments through March 6, 2027.

Remarks:

General Counsel and Chief Adminstrative Officer

	/s/ Traci S. Umberger	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-438662.

KESTRA MEDICAL TECHNOLOGIES, LTD.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Umberger Traci S trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4